Sedivention GmbH

It was a great experience to attend the MedFIT Event in Lille, France. Many inspiring meetings, very good presentations, lots of learnings.

It was a privilege and a pleasure to participate in the annual meeting of the Nordic Mentor Network For Entrepreneurship - NOME, supported by the Novo Nordisk Foundation. Sedivention GmbH was honoured to be admitted to the NOME Pitch competition from about 230 applicants, together with MyCural Therapeutics, Biomensio Ltd, Kiox Pharmaceuticals, Lifecare, and, congratulations to Umaima Malik Ahmad, 52North - creators of Neutrocheck®. Many thanks to Peter Birk and Rebecca Guacan Carlosama for this marvellous day in Copenhagen.

✨ Celebrating Innovation at the NOME Annual Meeting 2024! ✨ What a fantastic gathering of innovation, collaboration, and entrepreneurship at this year’s NOME Annual Meeting! It was inspiring to witness groundbreaking ideas from some of the most promising startups across the life sciences and healthcare sectors. A huge congratulations to the finalists – 52North - creators of Neutrocheck®, Biomensio Ltd, Sedivention GmbH, Kiox Pharmaceuticals, Lifecare, and MyCural Therapeutics – for their outstanding pitches. Special applause to 52North and Umaima Malik Ahmad, the winner of this year’s NOME Prize, for their impactful work! 🏆 We are especially proud of MyCural Therapeutics and Alina Castell, one of our own from UIC - Uppsala Innovation Centre, for standing out as one of the finalist among more than 200 applicant companies. This is a remarkable achievement, and we are excited to continue supporting their journey of innovation and growth. The day continued with inspiring sessions, from networking and alumni presentations to a thought-provoking keynote by Jan van de Winkel, Ph.D., and concluded with celebrations honoring mentorship, scaleups, and the entrepreneurial spirit. A heartfelt thank you to the Nordic Mentor Network For Entrepreneurship - NOME organizing team for curating such a memorable and impactful event. Here’s to continued success for all the startups who participated! 🚀 #Innovation #Startup #lifescience #Entrepreneurship

Sedivention GmbH, a medical technology startup based in Straßlach, Germany, has secured €800,000 in pre-seed funding to advance its innovative obesity treatment device. https://lnkd.in/g3icsBsY

#Obesity is projected to affect 1.5 billion people by 2030, and it already causes 3.7 million deaths annually. At #Sedivention, we are committed to addressing this global health crisis with our innovative medical device.    HTGF | High-Tech Gründerfonds has invested €800k in #Sedivention, which allows us to advance product development and preclinical testing of our prototype which has already proven safe and effective.   Our cryocatheter ablates the gastric branches of the vagus nerve within minutes. The vagus nerve plays an important role in the dysregulation between food intake and satiety. This will also have a positive impact on obesity-related comorbidities such as #diabetes and hypertension.   #Obesity is not a consequence of lack of discipline, it is a disease. We help people lose weight. Without surgery, without implants, without lifelong medication.

We are happy and proud to announce that Sedivention has been accepted into the prestigious Creative Destruction Lab (CDL) program. CDL is a non-profit program for massively scalable #science based seed stage companies.This is another important step in the journey of Sedivention towards redefining obesity therapy. Many thanks to CDL, especially to our mentors. #BuildSomethingMassive.

Inspiring meetings and important learnings at the Healthtech in Munich